Monalizumab

  (Redirected from IPH2201)

Monalizumab (formerly IPH2201) is an investigational drug being studied for rheumatoid arthritis, gynecologic malignancies[1] and other cancers.[2][3]

Monalizumab
Monoclonal antibody
Type?
SourceHumanized
TargetNKG2A
Legal status
Legal status
  • Investigational
Identifiers
CAS Number
ChemSpider
  • none
UNII

Mechanism of actionEdit

Monalizumab is a monoclonal antibody targeted at NKG2A.[4] It is a checkpoint inhibitor.[5]

ReferencesEdit

  1. ^ A Dose-Ranging Study of IPH2201 in Patients With Gynecologic Malignancies
  2. ^ IPH2201 studies
  3. ^ First Clinical Data For Monalizumab As A Single Agent In Cancer Patients Show Favorable Safety Profile
  4. ^ AstraZeneca Inks $1.8B in Immuno-Oncology Deals as Q1 Profit Dips
  5. ^ "monalizumab". Archived from the original on 2016-12-20. Retrieved 2016-12-09.